Cart
sales@molnova.com
Atrosab
CAS No. 1365659-05-7
Atrosab( —— )
Catalog No. M37265 CAS No. 1365659-05-7
Atrosab is a humanized IgG1 antibody targeting TNFR1, inhibiting TNF-mediated apoptosis, and can be used to study inflammatory and neurodegenerative diseases.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 588 | In Stock |
|
| 10MG | 938 | In Stock |
|
| 25MG | 1397 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAtrosab
-
NoteResearch use only, not for human use.
-
Brief DescriptionAtrosab is a humanized IgG1 antibody targeting TNFR1, inhibiting TNF-mediated apoptosis, and can be used to study inflammatory and neurodegenerative diseases.
-
DescriptionAtrosab is a humanized IgG1 antagonistic anti-TNFR1 antibody. Atrosab inhibits TNF-mediated apoptosis induction and IL-6 and IL-8 production. Atrosab can be used for research of inflammatory disease.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayApoptosis
-
TargetApoptosis
-
RecptorApoptosis
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1365659-05-7
-
Formula Weight146.12 kDa.
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Zettlitz KA, et al. ATROSAB, a humanized antagonistic anti-tumor necrosis factor receptor one-specific antibody. MAbs. 2010 Nov-Dec;2(6):639-47.?
molnova catalog
related products
-
NVS-CECR2-1
NVS-CECR2-1 is a selective cat eye syndrome chromosome region candidate 2 (CECR2) inhibitor with antitumor activity and inhibits chromatin binding of CECR2 BRD. NVS-CECR2-1 is cytotoxic and can induce apoptosis.
-
3BDO
3BDO is a new mTOR activator. 3BDO inhibits autophagy.
-
TMI-1
TMI-1 (WAY-171318), a novel orally active inhibitor of ADAM17 (TACE) and MMP, induces tumor apoptosis in a breast cancer.
